Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study on treatment for Ph+ Acute Lymphoblastic Leukemia

Trial Profile

A Phase II Study on treatment for Ph+ Acute Lymphoblastic Leukemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2019

At a glance

  • Drugs Nilotinib (Primary) ; Antineoplastics
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2019 Results published in the Annals of Hematology
    • 08 Dec 2015 Status changed from recruiting to active, no longer recruiting as result presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top